Journal of Neurology | March 10, 2021
Aamodt AH, Høgestøl EA, Popperud TH, Holter JC, Dyrhol-Riise AM, Tonby K, Stiksrud B, Quist-Paulsen E, Berge T, Barratt-Due A, Aukrust P, Heggelund L, Blennow K, Zetterberg H and Harbo HF
Journal of neurology. 2021:1-10
DOI: https://doi.org/10.1007/s00415-021-10517-6
Abstract
Objective To test the hypotheses that blood biomarkers for nervous system injury, serum concentrations of neurofilament
light chain protein (NfL) and glial fibrillary acidic protein (GFAp) can serve as biomarkers for disease severity in COVID-
19 patients.
Methods Forty-seven inpatients with confirmed COVID-19 had blood samples drawn on admission for assessing serum
biomarkers of CNS injury by Single molecule array (Simoa), NfL and GFAp. Concentrations of NfL and GFAp were analyzed
in relation to symptoms, clinical signs, inflammatory biomarkers and clinical outcomes. We used multivariate linear models
to test for differences in biomarker concentrations in the subgroups, accounting for confounding effects.
Results In total, 21% (n = 10) of the patients were admitted to an intensive care unit, and the overall mortality rate was
13% (n = 6). Non-survivors had higher serum concentrations of NfL (p < 0.001) upon admission than patients who were
discharged alive both in adjusted analyses (p = 2.6 × 10–7) and unadjusted analyses (p = 0.001). The concentrations of NfL in non-survivors increased over repeated measurements; whereas, the concentrations in survivors were stable. The GFAp concentration was also significantly higher in non-survivors than survivors (p = 0.02).
Conclusion Increased concentrations of NfL and GFAp in COVID-19 patients on admission may indicate increased mortality
risk. Measurement of blood biomarkers for nervous system injury can be useful to detect and monitor CNS injury in
COVID-19.
Poster Background Reliable and reproducible antibody barcoding is critical for spatial biology workflows onthe Akoya PhenoCycler®-Fusion 2.0 (PCF). We evaluated and optimized a complementarychemistry to the existing Antibody Conjugation Kit…
Neurology
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Neurology
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
